🧬 This Week in Gene & Cell Therapy: EU CAR-T Rollout, RMAT for Dravet, DMD Trial Insights and More!
From Israel’s contribution to a game-changing EU CAR-T initiative to fresh RMAT designations and detailed Phase 2 data in bladder cancer, this week’s episode brings the top headlines transforming gene and cell therapy. Whether you’re tracking in vivo gene delivery tech, neuroimmunology pipelines, or exploring new trial designs for myasthenia gravis, this episode is packed with crucial updates that matter. 🔬💡
🔍 Highlights in this episode:
🌍 Israeli researcher joins €8M EU EASYGEN CAR-T delivery initiative
🏥 Saudi FDA approves first in-hospital CAR-T trial for adult ALL
🧪 LEGEND Phase 2 data shows 71% CR with detalimogene voraplasmid in NMIBC
🏠Fresenius and Charles River back EU bedside CAR-T manufacturing platform
🔬 Vyriad & Weizmann license innovative in vivo gene delivery system
🧠FDA grants RMAT to ETX101 for SCN1A-positive Dravet syndrome
🌿 Hope Biosciences earns RMAT for stem cell therapy in RRMS
🧩 Kyverna reveals Phase 3-ready CAR-T design for myasthenia gravis
đź“š DMD study identifies 6 key factors shaping gene therapy trial preferences
This isn’t just a roundup—it’s your essential guide to the innovations redefining gene and cell therapy worldwide. From AAV to CRISPR to stem cells, we’ve got the developments that count. 🎯
📢 Stay Ahead in Gene & Cell Therapy Research!
âś… Like, share, and subscribe for weekly updates on gene and cell therapy, rare diseases, and groundbreaking biotech
#GeneTherapy #CellTherapy #BiotechNews #CAR_T #DravetSyndrome #RRMS #BladderCancer #DMD #CRISPR #RMAT #BiotechInnovation #LucidQuest #LQVentures #GMP #ClinicalTrials #Neuroimmunology